Today: 19 April 2026
Glencore share price slips as Rio Tinto “put up or shut up” deadline looms — what traders watch next
27 January 2026
1 min read

Glencore share price slips as Rio Tinto “put up or shut up” deadline looms — what traders watch next

LONDON, Jan 27, 2026, 08:19 GMT — Regular session.

  • Glencore shares slipped roughly 1% in early London trading, retreating from recent gains near 52-week highs
  • Takeover Panel confirms Feb. 5 deadline remains for any Rio Tinto bid; new dealing disclosures submitted
  • HSBC scales back its view on Glencore ahead of the miner’s production update due later this week

Glencore plc shares slipped 4.95 pence, or 1.0%, to 495.15 pence by 0820 GMT, moving in a range from 494.65 to 499.55. Copper futures dropped close to 2% during that period, weighing on miners’ stocks.

The pullback coincides with renewed focus on the UK takeover timetable. The Takeover Panel’s disclosure table names Rio Tinto as the potential offeror, setting a 5 p.m. London deadline on Feb. 5 for Rio to either make a firm offer or withdraw—unless more time is granted.

Glencore revealed earlier this month that it’s in initial talks with Rio Tinto about a potential merger but cautioned there’s no guarantee a deal will happen. The company also outlined the position and dealing disclosure rules that come into effect during an offer period.

More disclosures rolled in Tuesday. Superannuation and Investments HoldCo Pty Ltd filed a Form 8.3 revealing it owned Glencore shares and had made a minor sale, the document showed.

Broker moves stirred the chatter. HSBC downgraded Glencore to “hold” and pegged a 515 pence price target, according to a broker ratings roundup hosted on the LSE. London South East

The broader market stayed firm—up until Tuesday’s drop. London stocks closed flat on Monday, yet industrial metal miners climbed 1.4%, while precious metal miners reached record peaks, Reuters reported.

The takeover story has two sides. When Rio and Glencore announced renewed talks earlier this month, investors immediately focused on how Glencore’s coal holdings would factor in. Some traders have raised concerns about potential divestments and regulatory barriers should a mega-deal move forward.

Who else could jump into the fray? Richard Hatch, an analyst at Berenberg, pointed to BHP as the “most likely interloper to this deal,” telling Reuters earlier this month. Reuters

At this stage, the market is mainly reacting to headlines and filings. As the Feb. 5 deadline approaches, expect the stock to move sharply on any sign of an extension request, a walk-away comment, or a change in tone from either party.

Glencore’s next key dates are its full-year production report on Jan. 29 and preliminary results set for Feb. 18, both at 0700 UK time, according to the company’s investor calendar.

Stock Market Today

  • ATI Share Price Surges 262% in One Year, But Valuation Flags Overvaluation
    April 18, 2026, 9:38 PM EDT. Shares of ATI have surged 261.9% over the past year to close at $164.66, fueled by interest in its Aerospace & Defense role. Despite strong gains, ATI scores 0 out of 6 on valuation checks. A Discounted Cash Flow (DCF) model estimates ATI's intrinsic value at approximately $142.92 per share, suggesting the stock is overvalued by 15.2%. The DCF uses projected free cash flows rising from $362.7 million to $1.19 billion by 2035. Investors are questioning whether current prices reflect fundamentals or if sentiment has outpaced growth prospects. Price-to-Earnings (P/E) ratios remain a quick gauge of value, linking share price to current earnings, but must account for growth and risk outlooks. ATI's elevated valuation hints at potential risks despite stellar price momentum.

Latest article

Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

18 April 2026
Definium Therapeutics shares rose to $22.68 after Stifel and Piper Sandler initiated coverage with Buy ratings, citing late-stage trials of DT120, an LSD-based tablet for anxiety and depression. The company will host an investor day April 22 in New York to discuss upcoming Phase 3 data. DT120 is in four pivotal studies, with top-line results expected through 2026. Johnson & Johnson and Compass Pathways are advancing rival clinic-based psychiatric drugs.
HSBC stock jumps in Hong Kong as Hang Seng delisting nears and profit-target talk builds
Previous Story

HSBC stock jumps in Hong Kong as Hang Seng delisting nears and profit-target talk builds

Unilever stock price today: ULVR nudges up as Goldman trims target, results loom
Next Story

Unilever stock price today: ULVR nudges up as Goldman trims target, results loom

Go toTop